Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
ketoprofen
Sanofi-Aventis Australia Pty Ltd
Medicine Registered
Registered
ORUDIS ® SUPPOSITORIES O r u d i s ® S u p p o s i t o r i e s CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING ORUDIS SUPPOSITORIES? Orudis Suppositories contains the active ingredient ketoprofen. Orudis Suppositories is used to treat the symptoms of rheumatoid arthritis and osteoarthritis. For more information, see Section 1. Why am I using Orudis Suppositories? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE ORUDIS SUPPOSITORIES? Do not use if you have ever had an allergic reaction to ketoprofen, aspirin or any other anti-inflammatory drugs, or any of the ingredients listed at the end of the CMI. Do not use if you have a peptic ulcer; problems with your heart; severe kidney or liver problems. Do not use if you are in your third trimester of pregnancy. The use of Orudis Suppositories during the first and second trimester of pregnancy should be avoided, as the safety of Orudis Suppositories in pregnant women has not been evaluated. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use Orudis Suppositories? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with Orudis Suppositories and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE ORUDIS SUPPOSITORIES? • The usual dose for this medicine is one suppository (100mg) at night. • Follow the instructions provided and use Orudis Suppositories until your doctor tells you to stop. More instructions can be found in Section 4. How do I use Orudis Suppositories? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING ORUDIS SUPPOSITORIES? THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist you visit that you are using Orudis Supp Read the complete document
orudis-ccdsv11-piv20-02dec20 Page 1 of 17 AUSTRALIAN PRODUCT INFORMATION – ORUDIS ® SR CAPSULES AND ORUDIS ® SUPPOSITORIES (KETOPROFEN) 1 NAME OF THE MEDICINE Ketoprofen 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Orudis suppository contains ketoprofen 100 mg. Each Orudis SR capsule contains ketoprofen 200 mg. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Orudis: Suppositories: White or cream torpedo-shaped suppositories. Orudis SR Capsules: modified release, hard gelatin capsule. Clear pink base & white opaque cap. Base and cap printed ‘ORUDIS SR 200’ and contains off-white to cream spherical pellets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Rheumatoid arthritis, osteoarthritis. 4.2 DOSE AND METHOD OF ADMINISTRATION After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used (see Section 4.4 Special warnings and precautions for use). Patients on long term treatment should be reviewed regularly with regards to efficacy, risk factors and ongoing need for treatment. ORUDIS SUPPOSITORIES: Normal suppository dosage is 1 suppository (100 mg) late at night supplemented as required with Orudis capsules during daytime. Orudis suppositories are especially appropriate for controlling overnight symptoms (severity of night and morning pain; duration and severity of morning stiffness). Suppositories administered late at night provide more consistent effective control of overnight symptoms than oral medication. ORUDIS SR (SUSTAINED RELEASE) CAPSULES: 100 to 200 mg once daily depending on the patient’s weight and on the severity of symptoms. Orudis SR should be taken with food. orudis-ccdsv11-piv20-02dec20 Page 2 of 17 USE IN THE ELDERLY: It is generally advisable in the elderly to begin ketoprofen therapy at the lower end of the dosage range and to maintain such patients on the lowest effective dosage. 4.3 CONTRAINDICATIONS Active or a history of gastrointestinal inflammatory d Read the complete document